S&P 500   5,252.29 (+0.07%)
DOW   39,739.39 (-0.05%)
QQQ   444.74 (-0.02%)
AAPL   170.80 (-1.45%)
MSFT   421.11 (-0.08%)
META   489.33 (-0.92%)
GOOGL   150.54 (-0.22%)
AMZN   180.79 (+0.53%)
TSLA   177.68 (-1.20%)
NVDA   906.12 (+0.40%)
NIO   4.63 (-0.86%)
AMD   181.56 (+1.10%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.23 (+1.30%)
MU   118.36 (-0.65%)
CGC   9.29 (-2.72%)
GE   175.04 (-2.82%)
DIS   122.08 (+0.91%)
AMC   3.80 (-12.44%)
PFE   27.89 (+0.40%)
PYPL   67.14 (+0.86%)
XOM   115.66 (+0.60%)
S&P 500   5,252.29 (+0.07%)
DOW   39,739.39 (-0.05%)
QQQ   444.74 (-0.02%)
AAPL   170.80 (-1.45%)
MSFT   421.11 (-0.08%)
META   489.33 (-0.92%)
GOOGL   150.54 (-0.22%)
AMZN   180.79 (+0.53%)
TSLA   177.68 (-1.20%)
NVDA   906.12 (+0.40%)
NIO   4.63 (-0.86%)
AMD   181.56 (+1.10%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.23 (+1.30%)
MU   118.36 (-0.65%)
CGC   9.29 (-2.72%)
GE   175.04 (-2.82%)
DIS   122.08 (+0.91%)
AMC   3.80 (-12.44%)
PFE   27.89 (+0.40%)
PYPL   67.14 (+0.86%)
XOM   115.66 (+0.60%)
S&P 500   5,252.29 (+0.07%)
DOW   39,739.39 (-0.05%)
QQQ   444.74 (-0.02%)
AAPL   170.80 (-1.45%)
MSFT   421.11 (-0.08%)
META   489.33 (-0.92%)
GOOGL   150.54 (-0.22%)
AMZN   180.79 (+0.53%)
TSLA   177.68 (-1.20%)
NVDA   906.12 (+0.40%)
NIO   4.63 (-0.86%)
AMD   181.56 (+1.10%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.23 (+1.30%)
MU   118.36 (-0.65%)
CGC   9.29 (-2.72%)
GE   175.04 (-2.82%)
DIS   122.08 (+0.91%)
AMC   3.80 (-12.44%)
PFE   27.89 (+0.40%)
PYPL   67.14 (+0.86%)
XOM   115.66 (+0.60%)
S&P 500   5,252.29 (+0.07%)
DOW   39,739.39 (-0.05%)
QQQ   444.74 (-0.02%)
AAPL   170.80 (-1.45%)
MSFT   421.11 (-0.08%)
META   489.33 (-0.92%)
GOOGL   150.54 (-0.22%)
AMZN   180.79 (+0.53%)
TSLA   177.68 (-1.20%)
NVDA   906.12 (+0.40%)
NIO   4.63 (-0.86%)
AMD   181.56 (+1.10%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.23 (+1.30%)
MU   118.36 (-0.65%)
CGC   9.29 (-2.72%)
GE   175.04 (-2.82%)
DIS   122.08 (+0.91%)
AMC   3.80 (-12.44%)
PFE   27.89 (+0.40%)
PYPL   67.14 (+0.86%)
XOM   115.66 (+0.60%)
NASDAQ:GNFT

Genfit (GNFT) Stock Price, News & Analysis

$3.56
-0.09 (-2.47%)
(As of 09:30 AM ET)
Today's Range
$3.56
$3.56
50-Day Range
$3.34
$4.04
52-Week Range
$2.89
$4.75
Volume
161 shs
Average Volume
17,916 shs
Market Capitalization
$177.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Genfit MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
209.0% Upside
$11.00 Price Target
Short Interest
Bearish
0.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.29mentions of Genfit in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.23) to $0.51 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.56 out of 5 stars

Medical Sector

583rd out of 939 stocks

Biological Products, Except Diagnostic Industry

96th out of 156 stocks

GNFT stock logo

About Genfit Stock (NASDAQ:GNFT)

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

GNFT Stock Price History

GNFT Stock News Headlines

Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
GENFIT S.A.
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Genfit SA ADR GNFT
GENFIT Reports Third Quarter 2023 Financial Information
Genfit (NASDAQ: GNFT)
Kepler Capital Keeps Their Buy Rating on Genfit (GNFTF)
See More Headlines
Receive GNFT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
4/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:GNFT
Fax
N/A
Employees
154
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+209.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$28 million
Book Value
$2.00 per share

Miscellaneous

Free Float
47,742,000
Market Cap
$177.39 million
Optionable
Not Optionable
Beta
1.08
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Jean-Francois Mouney (Age 69)
    Co-Founder & Chairman of the Board
    Comp: $399.98k
  • Mr. M. Pascal Prigent (Age 56)
    Chief Executive Officer
    Comp: $606.19k
  • Prof. Bart Staels (Age 61)
    Co-Founder & Chairman of the Scientific Advisory Board
  • Mr. Thomas Baetz (Age 50)
    Chief Financial Officer
  • Mr. Pascal Caisey (Age 56)
    Chief Operating Officer
  • Dr. Meriam Kabbaj Ph.D. (Age 50)
    Chief Technology Officer
  • Dr. Dean W. Hum Ph.D. (Age 62)
    Chief Scientific Officer
    Comp: $771.34k
  • Mr. Jean-Christophe Marcoux (Age 46)
    Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG
  • Mr. Laurent Lannoo (Age 54)
    Corporate Secretary & Director of Legal Affairs
  • Ms. Stefanie Magner J.D. (Age 43)
    Chief Compliance Officer & Executive VP of International Legal Affairs

GNFT Stock Analysis - Frequently Asked Questions

Should I buy or sell Genfit stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genfit in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GNFT shares.
View GNFT analyst ratings
or view top-rated stocks.

What is Genfit's stock price target for 2024?

2 equities research analysts have issued 12 month target prices for Genfit's shares. Their GNFT share price targets range from $11.00 to $11.00. On average, they anticipate the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 209.0% from the stock's current price.
View analysts price targets for GNFT
or view top-rated stocks among Wall Street analysts.

How have GNFT shares performed in 2024?

Genfit's stock was trading at $3.85 on January 1st, 2024. Since then, GNFT stock has decreased by 7.5% and is now trading at $3.56.
View the best growth stocks for 2024 here
.

Are investors shorting Genfit?

Genfit saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 98,900 shares, an increase of 15.1% from the February 29th total of 85,900 shares. Based on an average trading volume of 18,700 shares, the days-to-cover ratio is presently 5.3 days. Approximately 0.2% of the company's stock are sold short.
View Genfit's Short Interest
.

When is Genfit's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 11th 2024.
View our GNFT earnings forecast
.

What is Jean-François Mouney's approval rating as Genfit's CEO?

3 employees have rated Genfit Chief Executive Officer Jean-François Mouney on Glassdoor.com. Jean-François Mouney has an approval rating of 29% among the company's employees. This puts Jean-François Mouney in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Genfit own?
When did Genfit IPO?

Genfit (GNFT) raised $132 million in an IPO on Wednesday, March 27th 2019. The company issued 5,000,000 shares at $26.33 per share. SVB Leerink and Barclays acted as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.

Who are Genfit's major shareholders?

Genfit's stock is owned by a variety of retail and institutional investors. Top institutional investors include Optiver Holding B.V. (0.17%) and OLD Mission Capital LLC (0.02%).

How do I buy shares of Genfit?

Shares of GNFT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GNFT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners